Mumbai-based Wanbury, one of India’s fast growing pharmaceutical company having a presence in Active Pharmaceutical Ingredient (API) global market and domestic branded formulation, has announced a net profit up 40% at Rs 10.3 crore in Q3FY24 versus Rs 7.4 crore in Q2FY24, its financial results for the third quarter and nine months ended December 31, 2023. 

The results declared for Q3 & 9MFY24 marks a significant milestone in the history of the company registering its highest ever quarterly EBITDA of Rs 22 crore and nine month EBITDA of Rs 54 crore which is 225% and 350% higher compared to the same periods last year.

This is attributed to increase in sales volume, besides yield improvement and process engineering initiatives on existing products has led to improved operating margins.

As a long-term strategy, the company plans to expand its API product portfolio and focus on different therapeutic areas which will propel sustainable growth.

Over the years our endeavour has been to reduce debt and as a result our debt currently stands at Rs 117 crore.